The specter of generic competition has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the outlook of related pharmaceutical stakes. While initial times saw significant profits, the exclusivity expiration has opened the path for discounted copies, possibly reducing profitability and presenting a s